A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE® (Empagliflozin, 10mg, 25mg, q.d.) in Korean Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Empagliflozin (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 20 Feb 2018 Planned End Date changed from 11 Aug 2020 to 30 Dec 2019.
- 20 Feb 2018 Planned primary completion date changed from 11 Aug 2020 to 30 Jun 2019.
- 17 Aug 2016 Status changed from not yet recruiting to recruiting.